HA-binding receptors, such as RHAMM and CD44, have been shown to be overexpressed on various cancer cell surfaces, further expanding the broad applicability of HA-based nanomedicines for active tumor-targeted drug delivery (Jiang et al., 2012). The gene discussed is CD44; the disease is cancer.